Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin

Deterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether prophylactic use of carvedilol can prevent doxorubicin-induced cardiotoxicity and...

Full description

Saved in:
Bibliographic Details
Published in:Indian heart journal 2018-12, Vol.70 (Suppl 3), p.S96-S100
Main Authors: Abuosa, Ahmed Mohamed, Elshiekh, Ayman Hassan, Qureshi, Kahekashan, Abrar, Mohammed Burhan, Kholeif, Mona A., Kinsara, Abdulhalim Jamal, Andejani, Abdulwahab, Ahmed, Adel H., Cleland, John G.F.
Format: Article
Language:English
Subjects:
Adult
Antibiotics, Antineoplastic - adverse effects
Antibiotics, Antineoplastic - therapeutic use
Antioxidants - therapeutic use
Cardiomyopathy
Carvedilol
Carvedilol - therapeutic use
Clinical and Preventive Cardiology
Double-Blind Method
Doxorubicin
Doxorubicin - adverse effects
Doxorubicin - therapeutic use
Ejection fraction
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasms - drug therapy
Prospective Studies
Stroke Volume - drug effects
Ventricular Dysfunction, Left - chemically induced
Ventricular Dysfunction, Left - physiopathology
Ventricular Dysfunction, Left - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Deterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether prophylactic use of carvedilol can prevent doxorubicin-induced cardiotoxicity and whether any observed effect is dose related. A prospective, randomized, double-blind study in patients treated with doxorubicin, comparing placebo (n = 38) with different doses of carvedilol [6.25 mg/day (n = 41), 12.5 mg/day (n = 38) or 25 mg/day (n = 37)]. The primary endpoint was the measured change in left ventricular ejection fraction (LVEF) from baseline to 6 months. LVEF decreased from 62 ± 5% at baseline to 58 ± 7% at 6-months (p = 0.002) in patients assigned to placebo but no statistically significant changes were observed in any of the 3 carvedilol groups. At 6 months, only one of 116 patients (1%) assigned to carvedilol had an LVEF 
ISSN:0019-4832
DOI:10.1016/j.ihj.2018.06.011